BYND CANNASOFT ENTERPRISES (BCAN)       3.36  0 (0%)

3.36  0 (0%)

CA05608P1099 - Common Stock - After market: 3.35 -0.01 (-0.3%)


Fundamental Rating

3

Overall BCAN gets a fundamental rating of 3 out of 10. We evaluated BCAN against 373 industry peers in the Software industry. BCAN has a great financial health rating, but its profitability evaluates not so good. BCAN is valued expensive and it does not seem to be growing.

Note: BCAN has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

The Piotroski-F score of BCAN is 3.00. This is a low score and indicates issues in the health and profitability of BCAN.

VS Industry

Valuation

Valuation Rating

1

With a price book ratio of 3.84, BCAN is valued correctly.
Compared to an average industry price book ratio of 3.27, BCAN is valued in line with its industry peers.

The Price/Earnings Ratio is negative for BCAN. In the last year negative earnings were reported.
VS Industry

Price/Book (3.84) VS Industry: 43% outperformed.

227.35
0.11

Growth

Growth Rating

2

The Earnings Per Share has grown by an impressive 87.20% over the past year.
BCAN shows a decrease in Revenue. Measured over the last 5 years, the Revenue has been decreasing by -7.60% yearly.

Looking at the last year, BCAN shows a very negative growth in Revenue. The Revenue has decreased by -58.34% in the last year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 87.2% N/A N/A N/A N/A
RevenueN/A -7.6% -58.34% N/A N/A N/A N/A

Health

Health Rating

8

A Current Ratio of 12.82 indicates that BCAN has no problem at all paying its short term obligations.
BCAN is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 1.76. BCAN has a better rating than 96% of its industry peers.
A Quick Ratio of 12.82 indicates that BCAN has no problem at all paying its short term obligations.
BCAN is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 1.74. BCAN has a better rating than 96% of its industry peers.

When comparing the Debt to Equity Ratio of 0.00 to an average industry Debt to Equity of 0.06, BCAN is way less dependent on financing that its industry peers.
An Altman-Z score of 226.02 indicates that BCAN is not in any danger for bankruptcy at the moment.
The Altman-Z score of BCAN is much better than the industry average of 1.81. BCAN has a better rating than 100% of its industry peers.
The Piotroski-F score of BCAN is 3.00. This is a low score and indicates issues in the health and profitability of BCAN.
VS Industry

Debt/Equity (0) VS Industry: 62% outperformed.

51.02
0.00

Quick Ratio (12.82) VS Industry: 96% outperformed.

0.06
83.89

Current Ratio (12.82) VS Industry: 96% outperformed.

0.06
83.89

Altman-Z (226.02) VS Industry: 100% outperformed.

-485.88
226.02

Dividend

Dividend Rating

0

No dividends for BCAN!.

BYND CANNASOFT ENTERPRISES3.36

NASDAQ:BCAN (1/27/2023, 7:00:00 PM)0 (0%)

After market: 3.35 -0.01 (-0.3%)

Chartmill FA Rating
GICS Sector Information Technology
GICS IndustryGroup Software & Services
GICS Industry Software
Earnings (Last) N/A N/A Earnings (Next) N/A N/A
Inst Owners N/A Inst Owner Change N/A
Ins Owners N/A Ins Owner Change N/A
Market Cap 126.80M Analysts N/A
Price Target N/A

Dividend
Dividend Yield N/A Dividend Growth N/A
DP 0% Ex-Date N/A

Surprises & Revisions
EPS beat(2) N/A Avg EPS beat(2) N/A
Min EPS beat(2) N/A Max EPS beat(2) N/A
EPS beat(4) N/A Avg EPS beat(4) N/A
Min EPS beat(4) N/A Max EPS beat(4) N/A
Revenue beat(2) N/A Avg Revenue beat(2) N/A
Min Revenue beat(2) N/A Max Revenue beat(2) N/A
Revenue beat(4) N/A Avg Revenue beat(4) N/A
Min Revenue beat(4) N/A Max Revenue beat(4) N/A
PT rev (1m) N/A EPS NQ rev (1m) N/A
EPS NY rev (1m) N/A Revenue NQ rev (1m) N/A
Revenue NY rev (1m) N/A

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 147.04
P/FCF N/A
P/OCF N/A
P/B 3.84
P/tB 38.75
EV/EBITDA N/A
EPS(TTM) -0.03 EY N/A
EPS(NY) N/A Fwd EY N/A
FCF(TTM) -0.04 FCFY N/A
OCF(TTM) -0.01 OCFY N/A
SpS 0.02 BVpS 0.88
TBVpS 0.09 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 58.19%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y 41.6% GM growth 5Y N/A
F-Score 3 Asset Turnover 0.03

Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13688.1%
Profit Quality N/A
Current Ratio 12.82
Quick Ratio 12.82
Altman-Z 226.02
F-Score 3 WACC 10.11%
ROIC/WACC N/A Cap/Depr(3y) 265%
Cap/Depr(5y) N/A Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 87.2% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -384.45%
EPS Next Y N/A EPS Next 2Y N/A
EPS Next 3Y N/A EPS Next 5Y N/A
Revenue growth 1Y -58.34% Revenue growth 3Y -7.6%
Revenue growth 5Y N/A Revenue growth Q2Q -23.1%
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
EBIT growth 1Y -201.91% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year N/A
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y -310.54% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -188.76%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA